P. Sergeev, I. Gushchin, M. Kaminka
Feb 1, 2002
Citations
0
Influential Citations
0
Citations
Journal
Pharmaceutical Chemistry Journal
Abstract
Diazoline (D), a selective blocker of H1 histamine receptors [1, 2], is used in clinics since the late 1960s. However, wide use of this drug is hindered by side effects, in particular, by the ulcerogenic action of diazoline [3 – 7]. Taking into consideration that zinc, being one of the major microelements controlling reactivity of the immune system, produces wound-healing, antiinflammatory, and antiulcerogenic effects [8], we have developed a new combined antiallergy preparation called diazin (D+) in the form of tablets containing diazoline (0.2 g) and zinc sulfate (0.01 g). Diazin was certified and registered under State Register Number 99/91/12 (18.03.99). The drug composition is selected so as to combine the average therapeutic dose of diazoline [2] with the recommended daily dose of zinc [9, 10].